Clinical trials: Heart Transplant Recipients
Heart Transplantation
Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients
Heart transplantation is a great procedure for selected patients with end-stage heart failure, but graft rejection remains a major factor limiting long-term survival despite continued advancement in the scientific skill of…
- Trial name
- NCT00169936
- Testing
- Magnetocardiograph
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Disorder Related to Cardiac Transplantation
Heart Transplant Registry of Városmajor
The purpose of this registry is to determine the long term outcomes of heart transplantations performed at the Semmelweis University Heart and Vascular Center.
- Trial name
- NCT02347371
- Where
- Hungary
- Volunteers
- 11 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Cardiac Allograft Vasculopathy
Microvascular Cardiac Allograft Vasculopathy Trial
The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).
- Trial name
- mCAV (NCT05826444)
- Testing
- Echocardiography, Magnetic resonance imaging, Magnetocardiography
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- German Heart Institute
Heart Transplant
Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients
Injury of transplant tissue by a transplant recipient's immune system continues to be the leading cause of graft rejection and recipient death.
- Trial name
- NCT00466804
- Testing
- Heart transplant
- Where
- 12 sites in United States
- Volunteers
- 263 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplant Patients, Recipients of a Kidney From a Non-Heart-Beating Donor
Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor
One of the greatest problems in renal transplantation is the shortage of donor kidneys. Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is accompanied with a high percentage of acute renal…
- Trial name
- ATG (NCT00733733)
- Testing
- ATG Fresenius
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Radboud University Medical Center
Heart Transplant Rejection, Heart Transplant Infection
TTV Viral Load in Heart Transplant Recipients
This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation.
- Conditions
- Heart Transplant Rejection, Heart Transplant Infection, Virus
- Trial name
- TTVCoeur (NCT05064462)
- Testing
- Collection of EDTA blood sample (5 to 7 ml)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Immunosuppression
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.
- Trial name
- TICTAC (NCT00299221)
- Testing
- Tacrolimus, combination therapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Newark Beth Israel Medical Center
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
Liver Transplant
Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.
The stress of orthotopic living donor liver transplantation in patients with cirrhosis could induce worsening of an already recorded myocardial dysfunction or may be associated with a new myocardial dysfunction in patients…
- Trial name
- NCT01840514
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Endocrine System Diseases, Thyroid Diseases
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
The aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients.
- Conditions
- Endocrine System Diseases, Thyroid Diseases, Cortisol Deficiency, Diabetes Insipidus
- Trial name
- NCT04351945
- Testing
- Blood test
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Graft Rejection
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
- Trial name
- NCT00300274
- Testing
- everolimus, mycophenolate mofetil, cyclosporine
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 721 people
- Sponsor
- Novartis Pharmaceuticals
Cardiorenal Syndrome, Chronic Allograft Nephropathy
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac…
- Trial name
- NCT01265615
- Testing
- Paricalcitol, Calcitriol, Cholecalciferol
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 109 people
- Sponsor
- Ural State Medical University
Heart Transplantation
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
In this study two immunosuppressive regimens (everolimus in combination with cyclosporine microemulsion and mycophenolate mofetil with cyclosporine microemulsion) with reduced dose cyclosporine microemulsion are compared in…
- Trial name
- NCT00170859
- Testing
- Everolimus
- Where
- Germany
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Recipient, Kidney Transplant; Complications
Vascular Complications After Kidney Transplantation
To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients…
- Conditions
- Kidney Transplant Recipient, Kidney Transplant; Complications, Transplant Renal Artery Stenosis, Renovascular Disease
- Trial name
- DAN-PTRAIII (NCT07531966)
- Testing
- Catheter-based angiography, Measurement of translesional pressure gradients, Intravascular ultrasound (IVUS)
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Cytomegalovirus Infections, Heart Transplantation
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients < 4 months of age.
- Trial name
- NCT01165580
- Testing
- valganciclovir [Valcyte]
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation, Cardiovascular Diseases
Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients
The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of…
- Trial name
- MMCR (NCT01213394)
- Testing
- mycophenolate mofetil, standard immunosuppression
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ramesh Prasad
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function.
- Trial name
- NCT01278745
- Testing
- Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
- Where
- 24 sites in United States
- Volunteers
- 362 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplant;Failure,Kidney, Transplant; Failure, Heart
EASE-SOT Pilot Study
Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life.
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Heart, Transplant; Failure, Liver, Transplant; Failure, Pancreas
- Trial name
- NCT06396702
- Testing
- EASE-SOT
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Heart Transplant Recipients
Mixing 1:1 HIIT and MICT in Early to Very Early Phase HTx Recipients : a Retrospective Study From a 510 Patients/12 Years Database
Background: Exercise-based cardiac rehabilitation is recommended early to very early for heart transplant recipients (HTRs), but data on its feasibility and efficacy at this stage are lacking.
- Trial name
- COMET-HT (NCT07132554)
- Testing
- Combined 1:1 MICT and HIIT aerobic cardiac rehabilitation
- Volunteers
- 510 people
- Sponsor
- Hôpital Léon Bérard